ValuEngine upgraded shares of Mylan (NASDAQ:MYL) from a hold rating to a buy rating in a research report released on Friday morning.
Other analysts have also recently issued research reports about the company. Mizuho reaffirmed a buy rating and issued a $37.00 target price (down previously from $53.00) on shares of Mylan in a research report on Sunday, August 20th. Citigroup raised Mylan from a neutral rating to a buy rating and raised their target price for the stock from $36.00 to $42.00 in a research report on Wednesday, August 16th. UBS reaffirmed a buy rating and issued a $46.00 target price (down previously from $50.00) on shares of Mylan in a research report on Thursday, August 10th. BMO Capital Markets reaffirmed a buy rating and issued a $45.00 target price on shares of Mylan in a research report on Friday, September 29th. Finally, BTIG Research raised their target price on Mylan from $42.00 to $45.00 and gave the stock a buy rating in a research report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $41.49.
Mylan (NASDAQ MYL) traded up $1.59 on Friday, hitting $38.12. The stock had a trading volume of 7,799,300 shares, compared to its average volume of 5,950,454. The company has a market cap of $20,448.95, a price-to-earnings ratio of 8.11, a PEG ratio of 2.09 and a beta of 1.38. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan has a 1-year low of $29.39 and a 1-year high of $45.87.
Several large investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. raised its holdings in Mylan by 76.9% during the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after buying an additional 1,475 shares in the last quarter. BT Investment Management Ltd bought a new position in Mylan during the third quarter valued at about $142,000. Global X Management Co. LLC raised its holdings in Mylan by 59.2% during the second quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after buying an additional 1,786 shares in the last quarter. Doliver Capital Advisors LP bought a new position in Mylan during the second quarter valued at about $201,000. Finally, Eagle Global Advisors LLC bought a new position in Mylan during the second quarter valued at about $205,000. Institutional investors and hedge funds own 73.86% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/04/mylan-myl-raised-to-buy-at-valuengine.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.